Are you up to date with the latest advancements in the management of HER2-positive NSCLC? Gain practical insights on biomarker testing, HER2-targeted therapies, and emerging treatment strategies with this free video podcast series:

Looking to refine your decision-making skills in decoding HER2 mutations and overexpression in NSCLC? Explore our free, CME-accredited case scenarios to unpick the latest clinical trial data and emerging treatment regimens for HER2 NSCLC:

World Lung is in full swing, which means the press releases are coming fast (before the papers or the sessions). 🫁 Why do we care in GI? Because all the shiny things start in lung and eventually make their way over here. HARMONi-2 compared ivonescimab vs pembrolizumab in PD-L1+ advanced NSCLC. We already knew the PFS result was kind of wild (in a China-only study): 11.1 vs 5.8 months HR 0.51 Now OS: 🔥 30.8 vs 22.6 months 🔥 HR 0.73 PD-L1 ≥50%: HR 0.58 PD-L1 1–49%: HR 0.85 So now this PD-1 x VEGF bispecific has beaten pembrolizumab for both PFS and OS in a randomized phase III trial. Yes, China only. Yes, pembro monotherapy is not really the comparator most of us would want for PD-L1 1–49%. Still. An 8-month OS difference is quite a bit. GI oncologists should be paying attention because this is already cooking in the first line mCRC setting with HARMONi-GI3. mFOLFOX6 + ivonescimab vs mFOLFOX6 + bevacizumab Is this an end-run around patent protection laws and PD1/PDL1's run out of time? (yes) Does the strategy have synergystic benefit? Time will tell. @OncoAlert @TheGutOncLab @Onco_Nexus